P.b.p Enterprises Private Limited

P.B.P Enterprises Private Limited is an Indian pharmaceutical exporter headquartered in Mumbai, Maharashtra. Established on August 21, 2018, the company operates under the Corporate Identification Number (CIN) U51909MH2018PTC312925. It is a private, unlisted entity with an authorized and paid-up capital of ₹500,000 each. The company's registered office is located at 10, Floor Grd, Plot 65, Ganapati Bhavan, Mahatma Jyotiba Phule Road, Naigaon Dadar East, Mumbai, Maharashtra, 400014.

P.B.P Enterprises specializes in the wholesale trading of pharmaceutical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. The company has been operational since its incorporation in 2018 and has been actively involved in the export of pharmaceutical products.

P.B.P Enterprises Private Limited does not own manufacturing facilities. Instead, it operates as a trader and wholesaler, sourcing pharmaceutical products from various manufacturers. The company emphasizes quality assurance by personally testing each batch of medications to ensure compliance with FDA standards. This approach allows P.B.P Enterprises to offer a broad range of pharmaceutical goods, including anti-cancer drugs, HIV medications, and nephrology drugs, without the overhead associated with manufacturing.

The leadership team at P.B.P Enterprises Private Limited comprises:

• Deepak Prakash Shete: Director
• Durvank Mohan Kamerkar: Director
• Gaurav Prakash Kamerkar: Director

These individuals have been instrumental in steering the company's operations and strategic direction since its inception.

P.B.P Enterprises Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has engaged in exporting products such as Regorafenib and Atovaquone, indicating a presence in therapeutic areas like oncology and infectious diseases. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. This lack of publicly accessible information suggests that P.B.P Enterprises may not have established a significant presence in these regulated markets.

P.B.P Enterprises Private Limited has been involved in exporting pharmaceutical products to various regions, including Africa, Latin America, and Southeast Asia. The company's engagement in these markets is facilitated by its adherence to international quality standards, ensuring that its products meet the necessary criteria for distribution in these regions. While specific details about WHO prequalification or other certifications are not publicly disclosed, the company's commitment to quality suggests a focus on meeting global standards to enhance market access.

P.B.P Enterprises Private Limited's export portfolio is concentrated in a limited number of products, with Regorafenib and Atovaquone accounting for the majority of its export value. This concentration indicates a focused approach in its product offerings. However, the lack of diversification in its product range may expose the company to risks associated with market fluctuations and regulatory changes affecting these specific products. Strategically, expanding its product portfolio and exploring new markets could mitigate such risks and enhance the company's resilience.

Specific information regarding P.B.P Enterprises Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. This absence of publicly accessible data suggests that the company may not have established a significant presence in the U.S. market or may not have pursued FDA approvals for its products. Without FDA approvals, the company's ability to market and distribute its pharmaceutical products in the United States would be limited.

There is no publicly available information indicating that P.B.P Enterprises Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The absence of such certifications may limit the company's ability to export its products to markets that require these standards. Obtaining WHO prequalification and EU GMP certifications could enhance the company's credibility and facilitate access to a broader range of international markets.

P.B.P Enterprises Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the necessary manufacturing licenses and approvals from state drug controllers to distribute pharmaceutical products within India. Additionally, P.B.P Enterprises has obtained the Exporter Importer Code (IEC) AAKCP0253H, which authorizes it to export pharmaceutical products.

As of March 28, 2026, there are no publicly available records indicating that P.B.P Enterprises Private Limited has received any Form 483 observations, warning letters, or import alerts from regulatory authorities. The absence of such records suggests that the company maintains a compliant status with regulatory bodies.

P.B.P Enterprises Private Limited operates in a competitive pharmaceutical export market, with numerous companies offering similar products. While specific market share data is not publicly available, the company's focus on high-demand therapeutic areas such as oncology and infectious diseases positions it in a competitive segment. To enhance its competitive edge, P.B.P Enterprises could consider diversifying its product portfolio, obtaining international certifications, and expanding its presence in regulated markets.

P.B.P Enterprises Private Limited's key differentiators include its specialization in finished pharmaceutical formulations and its commitment to quality assurance. The company's focus on high-demand therapeutic areas such as oncology and infectious diseases allows it to cater to critical healthcare needs. Additionally, P.B.P Enterprises' adherence to international quality standards, as evidenced by its compliance with FDA norms, enhances its credibility in the pharmaceutical export market.

P.B.P Enterprises Private Limited's current strategic direction appears to be focused on trading and wholesaling finished pharmaceutical formulations, with an emphasis on high-demand therapeutic areas. The company's future outlook could benefit from expanding its product portfolio, obtaining international certifications such as WHO prequalification and EU GMP, and exploring new markets to mitigate risks associated with product concentration and enhance growth prospects.

P.B.P Enterprises Private Limited has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $10,000 USD across seven shipments. The company's focus on high-demand therapeutic areas and its commitment to quality assurance indicate reliability in its operations. However, the concentration of its export portfolio in a limited number of products suggests that the company may benefit from diversifying its offerings to enhance resilience and reduce dependency on specific products.

Importers should verify the following certifications when considering P.B.P Enterprises Private Limited as a supplier:

• FDA Facility Registration: To confirm compliance with U.S. regulatory standards.
• WHO Prequalification: To ensure adherence to international quality standards.
• EU GMP Certification: To verify compliance with European manufacturing standards.
• ISO Certifications: To assess the company's quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the supplier.

When conducting due diligence on P.B.P Enterprises Private Limited, consider the following steps:

• Verify Regulatory Compliance: Confirm the company's adherence to relevant regulatory standards, including FDA, WHO, and EU GMP.
• Assess Financial Health: Review the company's financial statements to evaluate stability and profitability.
• Evaluate Product Portfolio: Examine the range and quality of products offered to ensure they meet your requirements.
• Check References: Seek feedback from other clients or partners to gauge reliability and performance.
• Inspect Facilities: If possible, visit the company's facilities to assess manufacturing capabilities and quality control measures.

Be cautious of red flags such as lack of transparency, inconsistent financial records, or absence of necessary certifications. Conducting thorough due diligence will help mitigate risks and ensure a successful partnership.